R. Steinberg

SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

Caroline Cohen, Ghislaine Perrault, C. Voltz et al. · Behavioural Pharmacology · 2002 · 392 citations

Neuropsychology, Receptor Antagonist, Dopamine-releasing Effects +20

In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist

Xavier Emonds‐Alt, Jean-Daniel Doutremepuich, Michel Héaulme et al. · European Journal of Pharmacology · 1993 · 373 citations

Signal Transduction, Vivo Biological Activities, Medicine +8

SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia

Philippe Pichat, Olivier Bergis, Jean-Paul Terranova et al. · Neuropsychopharmacology · 2006 · 237 citations · Full text

Psychiatry, Psychotic Disorder, Medicine +10

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1 S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine Hydrochloride (SSR125543A), a Potent and Selective Corticotrophin-Releasing Factor1 Receptor Antagonist. II. Characterization in Rodent Models of Stress-Related Disorders

Guy Griebel, Jacques Simiand, R. Steinberg et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 235 citations

Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic

Ronan Depoortère, Gihad Dargazanli, Genevieve Estenne‐Bouhtou et al. · Neuropsychopharmacology · 2005 · 217 citations · Full text

Neurophysiology, Medicine, Glycine Transporter-1 Ssr504734 +12